By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

The lessons learned from this study could inform more efficient vaccine development for other constantly evolving RNA viruses ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a new study.

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new ...

A new study shows how the technology deployed in Covid vaccines helped scientists coax the virus out of hiding. By Apoorva Mandavilli The technology that powered Covid vaccines may also lead ...

A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship ...

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, ...